The Hub for Disease-Specific Clinical Information
Advertisement
Advertisement

Disclosures

Jennifer R. Brown, MD, PhD

Associate Professor of Medicine, Dana-Farber Cancer Institute

Received clinical research support/data safety monitoring board from Invectys and MorphoSys AG.

Served on scientific advisory board or as a consultant or expert witness for AbbVie, Inc., Acerta Pharma, AstraZeneca Pharmaceuticals LP, BeiGene, Celgene Corporation, Novartis Pharmaceuticals Corporation, Sunesis Pharmaceuticals, Inc., and Verastem.

 

Daniel G. Coit, MD

Surgical Oncologist, Memorial Sloan Kettering Cancer Center, New York

Reported no conflicts of interest

 

David S. Ettinger, MD

Alex Grass Professor of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Received clinical research support/data safety monitoring board from Golden Biotechnology

Served on scientific advisory board or as a consultant or expert witness for AbbVie, BeyondSpring Pharmaceuticals, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech, Inc., and Guardant Health, Inc.

 

William J. Gradishar, MD

Director, Clinical Network; Chief, Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago

Served on scientific advisory board or as a consultant or expert witness for Genentech, Inc.

Served on promotional advisory board or speakers bureau for Genomic Health

Received patent, equity, or royalty from Biotheranostics and MGI Pharma, Inc.

 

Gabriela Hobbs, MD

Clinical Director, Leukemia Service at Massachusetts General Hospital

Received clinical research support/data safety monitoring board from Bayer HealthCare, 
Incyte Corporation, and Merck & Co., Inc.

Served on scientific advisory board or as a consultant or expert witness for Agios, Inc.
Celgene Corporation, and Incyte Corporation.

 

Prashant Kapoor, MD

Assistant Professor of Medicine and Oncology (Division of Hematology), Mayo Clinic, Rochester, Minnesota

Received clinical research support/data safety monitoring board from Takeda Pharmaceuticals North America, Inc., Amgen, Inc., Janssen Pharmaceutica Products, LP., and Sanofi-aventis U.S.

Served on scientific advisory board or as a consultant or expert witness for Sanofi-aventis U.S., Takeda Pharmaceuticals North America, Inc., with compensation to Mayo Clinic.

Involved in the development of Mayo Clinic mSMART guidelines.

 

Shaji K. Kumar, MD

Professor of Medicine, Mayo Clinic, Rochester, Minnesota

Received clinical research support/data safety monitoring board from Abbott Laboratories, Amgen, Inc., Bristol-Myers Squibb Company, Janssen Pharmaceutical Products, LP, Kite Pharma, MedImmune Inc., Merck & Co., Inc., Roche Laboratories, Inc., sanofi-aventis U.S., and Takeda Pharmaceuticals North America, Inc.

Served on scientific advisory board or as a consultant or expert witness for Abbott Laboratories, Amgen Inc., Celgene Corporation, Janssen Pharmaceutical Products, LP, Karyopharm, Kite, Merck & Co., Inc., Oncopeptides, Reddy’s Laboratory, and Takeda Pharmaceuticals North America, Inc.

 

Karl D. Lewis, MD

Associate Professor, Division of Medical Oncology, University of Colorado Denver School of Medicine

Received clinical research support from or served on data safety monitoring board for Regeneron Pharmaceuticals, Inc., and Roche Laboratories, Inc.

Served on scientific advisory board or as a consultant or expert witness for Genentech, Inc., Regeneron Pharmaceuticals, Inc., and Sun Pharma

 

Ursula A. Matulonis, MD

Professor of Medicine, Harvard Medical School; Director, Gynecologic Oncology; Brock-Wilson Family Chair, Dana-Farber Cancer Institute, Boston

Served on scientific advisory board or as a consultant or expert witness for 2X Oncology, AstraZeneca, Clovis, Fujifilm, Geneos, Myriad Genetic Laboratories, Syntax, and Tesaro

 

Michael J. Mauro, MD

Leader, Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York

Received clinical research support from or served on data safety monitoring board as principal investigator for Novartis Pharmaceuticals Corporation

Served on scientific advisory board or as a consultant or expert witness for Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Takeda Pharmaceuticals North America, Inc., and Pfizer, Inc.

 

James L. Mohler, MD

Associate Director and Senior Vice President of Translational Research; Chief, Inter-Institutional Academics; Professor of Oncology, Roswell Park Comprehensive Cancer Center

Reported no conflicts of interest

 

Robert J. Motzer, MD

Jack and Dorothy Byrne Chair in Clinical Oncology, Memorial Sloan Kettering Cancer Center, New York

Served as a consultant for Exelixis, Eisai, Genentech, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Incyte, Lilly Oncology, and Pfizer Inc. 

 

David G. Pfister, MD

Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York

Received clinical research support from or served on data safety monitoring board for AstraZeneca, Bayer HealthCare, Boehringer Ingelheim GmbH, Eli Lilly and Company, Exelixis Inc., Genentech, Inc., GlaxoSmithKline, Incyte Corporation, MedImmune Inc., Merck & Co., Inc., and Novartis Pharmaceuticals Corporation

Served on scientific advisory board or as a consultant or expert witness for Incyte Corporation and Merck & Co., Inc.

 

Michael A. Postow, MD

Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York

Received clinical research support from or served on data safety monitoring board for Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Array BioPharma, Infinity Pharmaceuticals, and Rgenix, Inc.

Served on scientific advisory board or as a consultant or expert witness for Bristol-Myers Squibb Company, Array BioPharma, Merck & Co., Inc., Incyte Corporation, and Newlink Genetics

 

Sandy Srinivas, MD

Professor of Medicine, Stanford University Medical Center

Has received clinical research support from or served on a data safety monitoring board for Bayer HealthCare, Clovis Oncology, Exelixis Inc., Janssen Pharmaceutica Products, LP, and Pfizer Inc. and has served as an advisor, consultant, or expert witness for Bayer HealthCare, Clovis Oncology, and Janssen Pharmaceutica Products, LP.

 

Vatche Tchekmedyian, MD

Hematologist and Oncologist, Maine Medical Center, Portland, ME

Holds stock in Infinity Pharmaceuticals, Inc., Halozyme Therapeutics, Inc., Global Blood Therapeutics, Portola Pharmaceuticals, Inc., Rigel Pharmaceuticals, Inc., and BioMarin Pharmaceutical

 

 

Medical Writers:

Melissa Eng

Serves as Research Coordinator at the Northwell Health Clinical Trials Office.

Lauren Harrison

Graduate student researcher at the University of Connecticut.

Nahae Kim

Serves as Assistant Research Coordinator for Northwell Health.

 

The following individuals contributing to JNCCN 360 reported no relevant conflicts of interest:

Angel Au-Yeung; Meg Barbor, MPH; Sarah Campen, PharmD; Joseph Cupolo; Cordi Craig; Celeste L. Dixon;  Dana A. Elya, MS, RD, CDN; Laura Entis; Joseph Fanelli; Andrew Goldstein; Emir Hadzic, PhD; Sarah Jackson; Julian Lim; Susan London; Margie Miller; Anna Nowogrodzki; Hillary Ojeda; Sylvia O’Regan; Susan Reckling; Kayci Reyer; Alison Tewksbury; and Sara Tewksbury

 

 

 

 

 

 



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.